Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | MAOA | P21397 | 4/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16589264 | 0.84 | FFAR1 (0.43) | PPARGFFAR1MAOAMAOBNPC1 | |
| SCHEMBL15583974 | 0.83 | MAOB (0.61) | PPARGFFAR1HTR2CMAOAMAOB | |
| SCHEMBL16592150 | 0.82 | MAOA (0.44) | PPARGHTR2CMAOAMAOBNPC1 | |
| SCHEMBL16592145 | 0.81 | HTR2C (0.64) | PPARGFFAR1HTR2CMAOAMAOB | |
| SCHEMBL16592154 | 0.79 | MAOB (0.60) | PPARGFFAR1HTR2CMAOAMAOB | |
| SCHEMBL16592160 | 0.78 | MAOA (0.41) | HTR2CMAOAMAOBNPC1RAB9A | |
| SCHEMBL16592127 | 0.75 | PPARG (0.46) | PPARGHTR2CMAOAMAOB | |
| SCHEMBL16592156 | 0.75 | HTR2C (0.44) | HTR2CMAOAMAOBNPC1RAB9A | |
| SCHEMBL15583971 | 0.75 | HTR2C (0.53) | PPARGHTR2CMAOAMAOBNPC1 | |
| SCHEMBL16592148 | 0.75 | HTR2C (0.67) | PPARGFFAR1HTR2CMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434695-B2 | Nitrogenous heterocyclic derivatives and their application in drugs | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2016-09-06 | — | — | US | disclosed |
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | TNNC1, TNNI3, IAPP | PPARG 2214/4885FFAR1 2244/4885HTR2C 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.